Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism LIV-1 inhibitors(Zinc transporter ZIP6 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Start Date05 Feb 2020 |
Sponsor / Collaborator |
Start Date09 Oct 2019 |
Sponsor / Collaborator Seagen Inc. [+1] |
Start Date27 Feb 2018 |
Sponsor / Collaborator Seagen Inc. [+1] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
stomach adenocarcinoma | Phase 2 | TW | 09 Oct 2019 | |
stomach adenocarcinoma | Phase 2 | GB | 09 Oct 2019 | |
Triple Negative Breast Cancer | Phase 2 | DE | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 2 | FR | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 2 | IL | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 2 | ES | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 2 | GB | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 1 | US | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 1 | AU | 02 Apr 2018 | |
Triple Negative Breast Cancer | Phase 1 | KR | 02 Apr 2018 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 81 | ladiratuzumab vedotin | (eamycjdohe) = pneumonia (6%) and abdominal pain (4%) lcplpnmtio (lfwyrryevx ) View more | Positive | 16 Sep 2021 |